The binding of the humanized antibody Hu1D10 to polymorphic HLA-DR molecules is sequence-dependent.

被引：0
|
作者：
Chang, PWC [1 ]
Mugiya, MM [1 ]
Jorgensen, BH [1 ]
Robinson, TJ [1 ]
Motchnik, PA [1 ]
Zhang, D [1 ]
Schneider, WP [1 ]
Tso, JY [1 ]
机构：
[1] Prot Design Labs Inc, Fremont, CA USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4682
引用
收藏
页码：239B / 239B
页数：1
相关论文
共 44 条
  • [1] In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells
    Shi, JD
    Bullock, C
    Hall, WC
    Wescott, V
    Wang, H
    Levitt, DJ
    Klingbeil, CK
    [J]. LEUKEMIA & LYMPHOMA, 2002, 43 (06) : 1303 - 1312
  • [2] A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study
    Rech, Juergen
    Repp, Roland
    Rech, Dorit
    Stockmeyer, Bernhard
    Dechant, Michael
    Niedobitek, Gerald
    Gramatzki, Martin
    Valerius, Thomas
    [J]. LEUKEMIA & LYMPHOMA, 2006, 47 (10) : 2147 - 2154
  • [3] IDENTIFICATION OF RESIDUES INVOLVED IN POLYMORPHIC ANTIBODY-BINDING EPITOPES ON HLA-DR MOLECULES
    FU, XT
    YU, WY
    ALBER, C
    BENSON, C
    WATTS, R
    NORDWIG, H
    JOHNSON, JP
    KNOWLES, RW
    KARR, RW
    [J]. HUMAN IMMUNOLOGY, 1992, 33 (01) : 47 - 56
  • [4] Critical Lym-1 binding residues on polymorphic HLA-DR molecules
    Rose, LM
    Deng, CT
    Scott, SL
    Xiong, CY
    Lamborn, KR
    Gumerlock, PH
    DeNardo, GL
    Meares, CF
    [J]. MOLECULAR IMMUNOLOGY, 1999, 36 (11-12) : 789 - 797
  • [5] COMPLEXITY OF ANTIBODY-BINDING EPITOPES ON HLA-DR MOLECULES
    FU, X
    KARR, RW
    [J]. CLINICAL RESEARCH, 1991, 39 (02): : A303 - A303
  • [6] THE MONOCLONAL-ANTIBODY AC1-59 DEFINES A NEW POLYMORPHIC DETERMINANT ON HLA-DR MOLECULES
    CREPALDI, T
    RICHIARDI, P
    MALAVASI, F
    CARBONARA, AO
    IGARASHI, M
    FERRONE, S
    [J]. TISSUE ANTIGENS, 1985, 26 (01): : 25 - 34
  • [7] Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen™ (Hu1D10).
    Link, BK
    Wang, H
    Byrd, JC
    Leonard, JP
    Davis, TA
    Flinn, I
    Hall, WC
    Turner, JF
    Bowles, J
    Shannon, M
    Levitt, D
    Weiner, GJ
    [J]. BLOOD, 2001, 98 (11) : 244B - 244B
  • [8] ROLE OF THE POLYMORPHIC RESIDUES IN HLA-DR MOLECULES IN ALLELE-SPECIFIC BINDING OF PEPTIDE LIGANDS
    MARSHALL, KW
    LIU, AF
    CANALES, J
    PERAHIA, B
    JORGENSEN, B
    GANTZOS, RD
    AGUILAR, B
    DEVAUX, B
    ROTHBARD, JB
    [J]. JOURNAL OF IMMUNOLOGY, 1994, 152 (10): : 4946 - 4957
  • [9] Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules
    Fridkis-Hareli, M
    Strominger, JL
    [J]. JOURNAL OF IMMUNOLOGY, 1998, 160 (09): : 4386 - 4397
  • [10] HLA-DR RESIDUES ACCESSIBLE UNDER THE PEPTIDE-BINDING GROOVE CONTRIBUTE TO POLYMORPHIC ANTIBODY EPITOPES
    FU, XT
    DROVER, S
    MARSHALL, WH
    KARR, RW
    [J]. HUMAN IMMUNOLOGY, 1995, 43 (04) : 243 - 250
12345